Story thread · 3 reports / 3 sources
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
cnbc.com · 3h · first report
How the coverage leans
Across 3 sources · syndicated copies counted once
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
The coverage
- Lilly says Zepbound combo delivered superior weight loss in mid-stage trial
seekingalpha.com · 2h
- Experimental Lilly combination drug tops Zepbound in weight-loss trial
reuters.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.